HK Stock Market Move | INSILICO (03696) rises nearly 8% again. The company announced a strategic alliance with Pfizer, with the potential total value expected to exceed 2.5 billion US dollars.

INSILICO (03696) rose nearly 8%, as of press time, it rose 7.56% to HK$49.82, with a turnover of HK$2.88 billion. On the news front, INSILICO announced that it has reached a strategic partnership alliance with Boli Pharmaceutical Co., Ltd. This alliance will be built on a wide-ranging, multidimensional cooperation framework, and the specific cooperation content will be further discussed and signed by both parties. If fully implemented, the potential total value of this cooperation is expected to exceed $2.5 billion. It is reported that the proposed cooperation under this alliance will be agreed upon by INSILICO and Boli through subsequent negotiations and signing of a final agreement. The aim is to integrate INSILICO's proprietary Pharma.AI platform's technological advantages in target discovery, chemical generation, and molecular optimization, as well as Boli's professional capabilities in global drug development, manufacturing, quality management, and commercialization. Through the integration of AI-enabled R&D systems with automated development, manufacturing, and quality execution processes, INSILICO and Boli aim to jointly create a new generation of drug innovation models, linking the design and development of novel molecules, manufacturing, and the ability to deliver drugs to patients with unmet medical needs.